West Technology Group, a diversified communication services company backed by Apollo Global Management [NYSE:APO], is in the early stages of exploring a sale for its TeleVox Software division, according to three sources familiar with the matter.

Mobile, Alabama-based TeleVox, a provider of multi-channel patient engagement software, is working with Goldman Sachs and RBC for the potential divest, which has not yet launched, the sources said.

TeleVox generates around USD 80m of EBITDA, the three sources said. The company generates around USD 130m in revenue, two of the sources said.

The seller is expected to reach out a broad group of potential buyers including financial sponsors and strategics, with a process expected to launch soon, one source said. A sale price could be in the USD 1bn neighborhood, the source added.

TeleVox serves more than 7,000 healthcare groups, including hospitals, health systems, life sciences companies and others, providing multi-channel communications with patients and doctors, according to a press release. TeleVox was purchased by West Technology in 2007 in a deal valued at USD 128m, according to Mergermarket’s database.

Omaha, Nebraska-based West Technology, formerly called Intrado Corp., was delisted from NASDAQ and taken private in 2017 by Apollo with an enterprise value of USD 5.2bn, according to a news release.

A sale of TeleVox would come amid a lively market for large and small healthcare information technology (HCIT) companies in recent months. Greenway Health, a large Vista Equity-backed HCIT firm, is exploring a sale via Macquarie, this news service reported last month. And RevSpring, another large HCIT provider backed by GTCR, is in a sale process via Morgan Stanley and TripleTree, this news service reported last November.

West Technology, Goldman Sachs and RBC declined to comment. Apollo and TeleVox didn’t respond to requests for comment by deadline.